CymaBay Therapeutics
CymaBay Therapeutics was a Hayward, California-based clinical-stage biopharmaceutical company developing seladelpar, a first-in-class PPAR-delta agonist for Primary Biliary Cholangitis and MASH, acquired by Gilead Sciences in 2024 for approximately $4.3–4.4 billion.
- Company typePrivate
- Founded1991
- HeadquartersHayward, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What CymaBay Therapeutics does
CymaBay Therapeutics was a Hayward, California-based clinical-stage biopharmaceutical company focused on developing proprietary small-molecule therapies for liver diseases. Its lead and primary asset was seladelpar, a first-in-class PPAR-delta agonist evaluated for Primary Biliary Cholangitis (PBC) — a rare autoimmune disease affecting the bile ducts — and for Metabolic dysfunction-Associated Steatohepatitis (MASH). Seladelpar received FDA accelerated approval in August 2024 and European Commission conditional marketing authorization in February 2025, becoming the first approved treatment for PBC patients in the European Economic Area. The company's underlying technology centered on selective PPAR-delta modulation, a differentiated mechanism of action within the PPAR receptor family that the company developed through Phase I–III clinical development.
During its independent operation, CymaBay functioned as a pre-commercial R&D entity with no product revenue. Development was funded through a mix of public equity offerings on NASDAQ (CBAY) and non-dilutive debt financing — including approximately $258.7 million raised in September 2023, $85 million planned in January 2023, $75 million in November 2021, and a $100 million non-dilutive facility from Abingworth in August 2021. The business model relied on advancing a single high-conviction asset through regulatory milestones rather than building a commercial sales force; revenue mechanics under independent ownership were limited to milestone payments and capital markets activity.
In 2024, Gilead Sciences acquired CymaBay for approximately $4.3–4.4 billion, integrating seladelpar into Gilead's liver disease franchise under the brand LivDelzi. Following the acquisition, CymaBay operates as a wholly-owned subsidiary of Gilead Sciences and no longer functions as an independent commercial entity.
CymaBay Therapeutics firmographics
Firmographics- Name
- CymaBay Therapeutics
- Legal name
- CymaBay Therapeutics, Inc.
- Website
- https://cymabay.com
- Company type
- Private
- Founded year
- 1991
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- CymaBay Therapeutics was a Hayward, California-based clinical-stage biopharmaceutical company developing seladelpar, a first-in-class PPAR-delta agonist for Primary Biliary Cholangitis and MASH, acquired by Gilead Sciences in 2024 for approximately $4.3–4.4 billion.
- Ownership category
- akta.pro rank
CymaBay Therapeutics industry classification
Industry- Product category
- Specialty Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
- akta.pro secondary industries
- Hepatology & Liver Disease (HLAKAEAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where CymaBay Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Hayward
- HQ country
- United States
- HQ region
- North America
Markets served
CymaBay Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
CymaBay Therapeutics product offering
Product offeringCore offering
CymaBay Therapeutics develops and commercializes proprietary biopharmaceutical therapies targeting liver diseases, with seladelpar as its lead asset. Seladelpar is a first-in-class PPAR-delta agonist for the treatment of Primary Biliary Cholangitis (PBC), a rare autoimmune liver disease, with additional development for Metabolic dysfunction-Associated Steatohepatitis (MASH). The drug received FDA accelerated approval in August 2024 and EU conditional marketing authorization in February 2025, and is now sold under the brand LivDelzi by Gilead Sciences following its acquisition of CymaBay.
Product overview
CymaBay Therapeutics was a biotech company focused on developing innovative therapies for liver diseases. The company's primary product was seladelpar, a drug candidate targeting Primary Biliary Cholangitis (PBC) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Following Gilead Sciences' acquisition of CymaBay in 2024 for approximately $4.3 billion, seladelpar was commercialized under the brand LivDelzi. The company conducted clinical trials across Phase I through Phase III stages and secured non-dilutive financing from Abingworth to support Phase 3 trials.
Differentiator
Problem solved
Functional benefit
Products and services
- Seladelpar (LivDelzi) Seladelpar is a first-in-class PPAR-delta agonist developed by CymaBay Therapeutics for the treatment of Primary Biliary Cholangitis (PBC), a rare autoimmune liver disease. It also targets Metabolic dysfunction-Associated Steatohepatitis (MASH). Following FDA accelerated approval in August 2024 and European Commission conditional marketing authorization in February 2025, the drug is commercialized by Gilead Sciences under the brand LivDelzi.
Quantifiable outcome
- FDA accelerated approval received August 2024
- +1 more outcomes
Companies that use CymaBay Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
CymaBay Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
CymaBay Therapeutics partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights4 records
CymaBay Therapeutics competitors and assessment
Company assessmentMarket position
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
CymaBay Therapeutics social profiles
Digital presenceCymaBay Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
CymaBay Therapeutics leadership team
Management profileNumber of profiles
Profiles10 records
CymaBay Therapeutics funding detail
Funding detailFunding overview
Funding rounds16 records
Investors24 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CymaBay Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CymaBay Therapeutics
What does CymaBay Therapeutics do?
CymaBay Therapeutics develops and commercializes proprietary biopharmaceutical therapies targeting liver diseases, with seladelpar as its lead asset. Seladelpar is a first-in-class PPAR-delta agonist for the treatment of Primary Biliary Cholangitis (PBC), a rare autoimmune liver disease, with additional development for Metabolic dysfunction-Associated Steatohepatitis (MASH). The drug received FDA accelerated approval in August 2024 and EU conditional marketing authorization in February 2025, and is now sold under the brand LivDelzi by Gilead Sciences following its acquisition of CymaBay.
Is CymaBay Therapeutics a public or private company?
CymaBay Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was CymaBay Therapeutics founded?
CymaBay Therapeutics was founded in 1991. It employs 51 to 100 people.
Where is CymaBay Therapeutics based?
CymaBay Therapeutics is headquartered in Hayward, United States, in the North America region.
Does CymaBay Therapeutics have an API?
No public API is recorded for CymaBay Therapeutics.
What industry is CymaBay Therapeutics in?
CymaBay Therapeutics's product category is Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAKAEAB, Hepatology & Liver Disease. Its NAICS code is 325414 and its SIC code is 2834.